A5013091160- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Neurogenesis and neuroplasticity mechanisms
- Amyotrophic Lateral Sclerosis Research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Skin and Cellular Biology Research
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Systemic Sclerosis and Related Diseases
- Multiple Myeloma Research and Treatments
- SARS-CoV-2 and COVID-19 Research
- Acute Lymphoblastic Leukemia research
- Neuroendocrine Tumor Research Advances
- Bacterial Infections and Vaccines
- Prion Diseases and Protein Misfolding
- T-cell and B-cell Immunology
- Mycobacterium research and diagnosis
- RNA regulation and disease
- Infectious Diseases and Tuberculosis
- Advanced Biosensing Techniques and Applications
- Neurosurgical Procedures and Complications
- Amyloidosis: Diagnosis, Treatment, Outcomes
Queen Mary University of London
2016-2025
Barts Health NHS Trust
2016-2025
Royal London Hospital
2015-2024
University College London
2012-2024
Monash University
2024
Monash Health
2024
Universitat Oberta de Catalunya
2024
Fundació Clínic per a la Recerca Biomèdica
2024
University of Siena
2024
UCL Biomedical Research Centre
2024
Ghrelin is a novel growth hormone-releasing peptide, originally identified in the rat stomach as endogenous ligand for hormone secretagogue-receptor (GHS-R1a). involved regulation of GH release, but it has recently been suggested that ghrelin may have other actions, including effects on appetite, carbohydrate metabolism, heart, kidney, pancreas, gonads, and cell proliferation. The distribution ghrelin, its functional receptor (type 1a) unspliced, non-functional GHS-R type 1b mRNA expression...
Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic workup of several neurological brain diseases. Reluctance to perform procedure among others due a lack standards and guidelines minimize risk complications, such as post-LP headache or back pain.We provide consensus for LP complications. The recommendations are based on (1) data from large multicenter feasibility study (evidence level II-2), (2) systematic literature review needle characteristics...
<h3>Objective:</h3> To investigate a potential effect of riluzole on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical MRI outcomes Nf levels. <h3>Methods:</h3> Serum samples were obtained from participants enrolled in randomized double-blind trial neuroprotection with vs as an add-on weekly interferon-β (IFN-β)–1a IM initiated 3 months after randomization. measurements performed by ELISA electrochemiluminescence immunoassay. <h3>Results:</h3>...
Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There now substantial evidence for this to be used alongside magnetic resonance imaging (MRI) clinical measures of disease progression as decision-making tool the management patients with MS. Serum NfL (sNfL) has certain advantages over traditional MS such MRI because it relatively noninvasive, inexpensive,...
The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research multiple sclerosis (MS). There a lack definitions and nomenclature different groups rationalized application groups. We here propose consensus for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease (INDCs), peripheral (PINDCs), non-inflammatory (NINDCs), symptomatic (SCs). Furthermore, we discuss these specific study designs,...
BackgroundNeurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test efficacy these an efficient manner with respect time, cost, patient resource.MethodsWe did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 neuroscience centres UK....
Abstract Neurofilament light chain is an established marker of neuroaxonal injury that elevated in CSF and blood across various neurological diseases. It increasingly used clinical practice to aid diagnosis monitor progression as outcome measure assess safety efficacy disease-modifying therapies the translational neuroscience field. Quantitative methods for neurofilament human biofluids have relied on immunoassays, which limited capacity describe structure protein how this might vary...
Our aim was to assess the real-world effectiveness of immune checkpoint inhibitors for treatment patients with progressive multifocal leukoencephalopathy (PML).We conducted a multicenter survey compiling retrospective data from 79 PML patients, including 38 published cases and 41 unpublished cases, who received as add-on standard care. One-year follow-up were analyzed determine clinical outcomes safety profile. Logistic regression used identify variables associated 1-year...
Cerebrospinal fluid (CSF) analysis is of utmost importance for diagnosis and differential patients with suspected multiple sclerosis (MS). Evidence intrathecal immunoglobulin G (IgG) synthesis proves the inflammatory nature disease, increases diagnostic certainty substitutes dissemination in time according to current criteria. The gold standard determine IgG detection CSF-restricted oligoclonal bands (OCBs). However, advances laboratory methods brought up κ-free light chains (FLCs) as a new...
Lamotrigine trial in SPMS was a randomised control to assess whether partial blockade of sodium channels has neuroprotective effect. The current study an additional investigate the value neurofilament (NfH) and other biomarkers predicting prognosis and/or response treatment.SPMS patients who attended NHNN or Royal Free Hospital, UK, eligible for inclusion were invited participate biomarker study. Primary outcome lamotrigine would significantly reduce detectable serum NfH at 0-12, 12-24 0-24...
Background: It was recently reported that, using Western blotting, some multiple sclerosis (MS) patients in the United States had antibodies against epsilon toxin (Etx) from Clostridium perfringens, suggesting that may play a role disease. Objective: We investigated for serum Etx UK with clinically definite (CDMS) or presenting isolated syndrome (CIS) optic neuritis (ON) and age- gender-matched controls. Methods: tested sera CDMS, CIS ON controls by blotting. also CDMS reactivity linear...
Abstract Objectives Neurofilament light chain (NfL) has emerged as a promising biomarker for detecting and monitoring axonal injury. Until recently, NfL could only be reliably measured in cerebrospinal fluid, but digital single molecule array (Simoa) technology enabled its precise measurement blood samples where it is typically 50–100 times less abundant. We report development multi-center validation of novel fully automated immunoassay serum informing injury status. Methods A 45-min was...
There are several options for switching people with multiple sclerosis (MS) who at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some these have risks that need be managed, example, the carrying over asymptomatic PML on new therapy, and rebound disease activity associated a prolonged washout after starting natalizumab. We propose pragmatic bridging strategy, using another disease-modifying therapy (DMT), reduce also discuss...
The cause of neurodegeneration in progressive forms multiple sclerosis is unknown. We investigated the impact specific neuroinflammatory markers on human neurons to identify potential therapeutic targets for neuroprotection against chronic inflammation. Surface immunocytochemistry directly visualized protease-activated receptor-1 (PAR1) and interleukin-1 (IL-1) receptors postmortem cortex patients with without lesions. Viability cultured was determined after exposure cerebrospinal fluid from...
Background: Biomarkers are needed to track progression in MS trials. Neurofilament heavy chain (NfH) has been underutilized due assay limitations. Objective: To investigate the added value of cerebrospinal fluid (CSF) NfH secondary progressive multiple sclerosis (SPMS) using contemporary immunoassays. Methods: This exploratory study was part MS-SMART trial. Clinical assessments (including expanded disability status scale, upper and lower limb function, visual acuity symbol digit modalities...
The COVID-19 pandemic highlighted the need for effective protection and rapid development of tests to track quantify seroconversion through natural infection vaccination. Recombinant proteins, consisting SARS-CoV-2 nucleocapsid Spike Receptor Binding Domains (RBD) fused with nanoluciferase reporters (GloBodies) were designed produced. specific antibody within serum, from venous blood or eluted local remotely-obtained dried spots, form a complex GloBody, which can be captured on immobilized...
Alemtuzumab was designed to reduce the immunogenicity of parent, CD52-specific, rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated treatment relapsing multiple sclerosis (Lemtrada®). Likely, due its history as first humanized antibody, potential molecule has been considered inconsequential, anti-drug antibodies (ADA) responses were similarly reported being clinically insignificant. Nonetheless, despite...